Linked Data API

Show Search Form

Search Results

1039028
star this property registered interest false more like this
star this property date less than 2019-01-10more like thismore than 2019-01-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Asparaginase more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether Erwinase will be available for the treatment for children with acute lymphoblastic leukaemia between January 2019 and March 2019; and if he will make a statement. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 207238 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-01-18more like thismore than 2019-01-18
star this property answer text <p>Erwinase is produced by Porton Biopharma Ltd (PBL) and is licensed and distributed by Jazz Pharmaceuticals under a global licencing agreement.</p><p> </p><p>Due to increased demand for Erwinase and because PBL are manufacturing at capacity, until increases in capacity are brought into beneficial use there will be occasional stock-outs.</p><p> </p><p>The product is currently in stock in the United Kingdom. The Department has been informed, it is likely there will be a short stock-out in early February 2019 and then a further batch is planned to be released to Jazz Pharmaceuticals, who are responsible for the packaging/distribution and allocation of worldwide product supply, anticipated to reach the UK market by mid-February 2019 which should last until the end of March 2019.</p><p> </p><p>The Department and Public Health England (PHE) are in close contact with, and have been kept informed by the PBL management of short periods of interrupted supply. PBL have and will be implementing a series of initiatives to increase capacity and better supply the market in both the short and long term. PBL are fully aware of the consequences that the unavailability of Erwinase has on patients and are absolutely committed to working with all involved to resolve any issues and be able to supply this critical medicine.</p><p> </p><p>The Department and PHE will continue to monitor the situation closely.</p>
star this property answering member constituency Winchester remove filter
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2019-01-18T12:18:00.113Zmore like thismore than 2019-01-18T12:18:00.113Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
1050101
star this property registered interest false more like this
star this property date less than 2019-01-28more like thismore than 2019-01-28
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Asparaginase more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 January 2019 to Question 207238 on Asparaginase, what steps Porton Biopharma will take to increase capacity of erwinase and better supply the (a) UK and (b) world market for the remainder of 2019. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 213322 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-02-05more like thismore than 2019-02-05
star this property answer text <p>Porton Biopharma Ltd (PBL) are implementing a series of initiatives to increase capacity and supply in both the short and long term. These include the following:</p><p>- Extending operational activities to 24 hours a day, seven days a week to maximise fermentation of the product;</p><p>- Implementing an ongoing capital programme including construction of a new pharmaceutical fermentation facility. The facility was completed in April 2018 and is currently undergoing testing; it has an increased capacity fermentation suite which will enable PBL to manufacture at larger scale and is due to start producing product Q3 2019 for regulatory approval to market;</p><p>- A new filling and freeze-drying building was completed in February 2016. The installation of a new filling line which covers the entire process, including vial washing, filling, stoppering and freeze drying. The new line has been designed with systems which monitor all critical parameters throughout the process to accelerate batch release and will accommodate increased capacity. The beneficial use of this and the fermentation facility will coincide to maximise increased product output; and</p><p>- Sourcing replacement suppliers, including for new stoppers and new vials for the product, ensuring that maximum batch sizes can be achieved with minimal product rejects. This programme is complete.</p><p> </p><p>PBL has made significant investments into increasing product capacity and will continue to release future batches as soon as they become available to Jazz Pharmaceuticals (who are responsible for the packaging/distribution and allocation of worldwide product supply).</p>
star this property answering member constituency Winchester remove filter
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2019-02-05T15:09:48.903Zmore like thismore than 2019-02-05T15:09:48.903Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
1017502
star this property registered interest false more like this
star this property date less than 2018-11-30more like thismore than 2018-11-30
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cancer more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what proportion of (a) leukaemia, (b) non-Hodgkin lymphoma, (c) Hodgkin lymphoma and (d) myeloma cases were diagnosed at each cancer stage in each of the last five years. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 197620 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-12-10more like thismore than 2018-12-10
star this property answer text <p>This information is not held centrally.</p> more like this
star this property answering member constituency Winchester remove filter
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-12-10T15:38:39.683Zmore like thismore than 2018-12-10T15:38:39.683Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
1060965
star this property registered interest false more like this
star this property date less than 2019-02-14more like thismore than 2019-02-14
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cancer: Counselling more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what plans the Government has to ensure that people with cancer are able to access psychological and emotional support. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 909320 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-02-19more like thismore than 2019-02-19
star this property answer text <p>By 2021, every person diagnosed with cancer will have access, where appropriate, to personalised care, including a needs assessment, a care plan and health and wellbeing information and support. The needs assessment guides a conversation about the person’s holistic needs (physical, psychosocial, financial and social) in order to identify any concerns, including psychological and emotional.</p> more like this
star this property answering member constituency Winchester remove filter
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2019-02-19T17:25:31.79Zmore like thismore than 2019-02-19T17:25:31.79Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
1002558
star this property registered interest false more like this
star this property date less than 2018-11-06more like thismore than 2018-11-06
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cancer: Medical Treatments more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the ability of the NHS long-term plan to (a) tackle the evolving challenges of cancer and (b) ensure that people are able to access personalised and tailored support after they have finished cancer treatment itself. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 188796 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-14more like thismore than 2018-11-14
star this property answer text <p>The NHS Long Term Plan provides an excellent opportunity to look at how cancer and other services can be further improved over the next decade. The plan is currently in development and will be published later in the year.</p> more like this
star this property answering member constituency Winchester remove filter
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-11-14T11:29:49.547Zmore like thismore than 2018-11-14T11:29:49.547Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
1050100
star this property registered interest false more like this
star this property date less than 2019-01-28more like thismore than 2019-01-28
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Haematological Cancer more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 March 2018 to Question 134294 on Haematological Cancer, when he plans for the evaluation of the rapid diagnostic centres to be published; and he plans for that evaluation to inform the national roll-out of the centres as proposed in the NHS Long-Term Plan. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 213321 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-02-05more like thismore than 2019-02-05
star this property answer text <p>Ten multi-disciplinary diagnostic centres are being piloted through the Accelerate, Co-ordinate, Evaluate (ACE) partnership between Cancer Research UK, Macmillan Cancer Support and NHS England. This pilot programme will end in March 2019. Early findings from those sites informed the plans for roll out of the Rapid Diagnostic Centres as part of the NHS Long Term Plan.</p><p> </p><p>During 2019/20, the ACE Programme will share further evaluation from the pilot centres. The findings will continue to inform plans for expansion of the Rapid Diagnostic Centres, alongside work being led by Cancer Alliances to improve early diagnosis.</p> more like this
star this property answering member constituency Winchester remove filter
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2019-02-05T15:31:33.267Zmore like thismore than 2019-02-05T15:31:33.267Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
987817
star this property registered interest false more like this
star this property date less than 2018-10-15more like thismore than 2018-10-15
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Haematological Cancer more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether the initiatives announced by the Prime Minister on 3 October 2018 on early detection rates for cancer include blood cancer; and if he will make a statement. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 179183 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-10-23more like thismore than 2018-10-23
star this property answer text <p>NHS England is completely clear that the new 75% early diagnosis ambition announced by the Prime Minister covers all cancers, and not just the 10 currently included in the Public Health Outcomes Framework (PHOF) early diagnosis metric. NHS England is keen to work with the voluntary sector organisations and charities representing some of the other cancers not currently included in the PHOF metric on how we best measure progress towards the ambition moving forwards.</p> more like this
star this property answering member constituency Winchester remove filter
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-10-23T16:57:18.817Zmore like thismore than 2018-10-23T16:57:18.817Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
994628
star this property registered interest false more like this
star this property date less than 2018-10-25more like thismore than 2018-10-25
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Haematological Cancer: Medical Treatments more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to the NHS England news releases of 5 September and 5 October, when he plans to make CAR-T cell therapy available to (a) people aged under 25 with acute lymphoblastic leukaemia and (b) adult patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after two or more previous therapies have failed. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 183918 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-02more like thismore than 2018-11-02
star this property answer text <p>NHS England is working with the manufacturers and National Health Service providers to prepare the NHS to begin delivering Chimeric Antigen Receptor T Cell (CAR-T) therapy - the first in a wave of treatments in a new era of personalised medicine and part of the NHS’s long-term plan to upgrade cancer service. The first treatment that will be available to patient is tisagenlecleucel (Kymriah) as an option for treating children and young people up to 25 years old with B cell acute lymphoblastic leukaemia that is refractory, in relapsed post-transplant or in second or later relapse.</p><p> </p><p>NHS England anticipates that the National Institute for Health and Care Excellence will recommend this treatment for entry into the Cancer Drugs Fund in mid-November. If so, funding will be made immediately available, following a successful commercial deal with the manufacturer Novartis. We anticipate the first patients will begin their treatment in late November 2018. The phased implementation required by the manufacturer and the NHS means that full capacity to treat eligible patients will take some months to achieve and a National CAR-T Clinical Panel will convene in mid-November to assure equity of access and prioritise eligible patients.</p>
star this property answering member constituency Winchester remove filter
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-11-02T13:32:27.747Zmore like thismore than 2018-11-02T13:32:27.747Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this